1204 related items for PubMed ID: 12860578
1. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
[Abstract] [Full Text] [Related]
2. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
Am J Kidney Dis; 2003 Mar 14; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[Abstract] [Full Text] [Related]
3. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.
J Am Soc Nephrol; 2007 May 14; 18(5):1540-6. PubMed ID: 17409317
[Abstract] [Full Text] [Related]
4. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B, Gleim G, Panish J.
Curr Med Res Opin; 2004 Dec 14; 20(12):1909-17. PubMed ID: 15701209
[Abstract] [Full Text] [Related]
5. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
Kidney Int; 2004 Jun 14; 65(6):2309-20. PubMed ID: 15149345
[Abstract] [Full Text] [Related]
6. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.
Diabetes Care; 2006 Oct 14; 29(10):2210-7. PubMed ID: 17003295
[Abstract] [Full Text] [Related]
7. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B.
Curr Med Res Opin; 2004 Mar 14; 20(3):333-40. PubMed ID: 15025842
[Abstract] [Full Text] [Related]
8. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
Rev Invest Clin; 2005 Mar 14; 57(3):399-405. PubMed ID: 16187699
[Abstract] [Full Text] [Related]
9. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S, RENAAL Study Investigators.
J Renin Angiotensin Aldosterone Syst; 2000 Dec 14; 1(4):328-35. PubMed ID: 11967819
[Abstract] [Full Text] [Related]
10. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME.
QJM; 2005 Feb 14; 98(2):119-26. PubMed ID: 15655096
[Abstract] [Full Text] [Related]
11. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
[Abstract] [Full Text] [Related]
12. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
Ugeskr Laeger; 2001 Oct 01; 163(40):5514-9. PubMed ID: 11601117
[Abstract] [Full Text] [Related]
13. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
[Abstract] [Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
Clin Ther; 2005 May 01; 27(5):578-87. PubMed ID: 15978306
[Abstract] [Full Text] [Related]
15. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM, RENAAL Study Investigators.
Clin J Am Soc Nephrol; 2006 Jul 01; 1(4):761-7. PubMed ID: 17699284
[Abstract] [Full Text] [Related]
16. Losartan in diabetic nephropathy.
Perico N, Ruggenenti P, Remuzzi G.
Expert Rev Cardiovasc Ther; 2004 Jul 01; 2(4):473-83. PubMed ID: 15225108
[Abstract] [Full Text] [Related]
17. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.
J Am Soc Nephrol; 2005 Jun 01; 16(6):1775-80. PubMed ID: 15872078
[Abstract] [Full Text] [Related]
18. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM, RENAAL Study Group.
J Am Soc Nephrol; 2004 Dec 01; 15(12):3117-25. PubMed ID: 15579515
[Abstract] [Full Text] [Related]
19. Pulse pressure and progression of chronic kidney disease.
Arulkumaran N, Diwakar R, Tahir Z, Mohamed M, Kaski JC, Banerjee D.
J Nephrol; 2010 Dec 01; 23(2):189-93. PubMed ID: 20119928
[Abstract] [Full Text] [Related]
20. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
Clin Ther; 2008 Sep 01; 30(9):1618-28. PubMed ID: 18840367
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
